Patent · US Active

Compositions and methods comprising digital signatures to predict response and resistance to targeted therapy and immunotherapy

US11505831B2 · kind B2 · utility

0Cited by
0References
18Claims
0Family size

Assignee

Inventors

Key dates

Filing dateDec 18, 2018
Grant dateNov 22, 2022
Priority date
Expiry dateFeb 10, 2040

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12Q2600/158
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

The present invention relates to gene expression signatures that predict response and resistance to targeted therapy and immunotherapy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.